COMMUNIQUÉS West-GlobeNewswire

Cosmos Health Enters $69 Billion Global Animal Health Industry with Veterinary C-Scrub Wash 4% Following Successful European Standard Testing Under EN 1656 and EN 1657
01/06/2026
CHICAGO, June 01, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced the extension of its C-Scrub [...]
Aura Biosciences Announces Enrollment Completion in Phase 3 CoMpass Trial of Bel-sar in Early Choroidal Melanoma
01/06/2026
Enrollment of 108 patients completed in the registration-enabling Phase 3 CoMpass trial Topline data from the 15-month primary endpoint expected in the second half of 2027 BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- Aura [...]
Oak Hill Bio Raises $32.5 Million Series A Financing to Advance Antisense Oligonucleotide Therapy Rugonersen to Phase 3 Study in Angelman Syndrome
01/06/2026
Series A financing co-led by Balyasny Asset Management, venBio, and Janus Henderson Investors Rugonersen, a potentially best-in-class antisense oligonucleotide (ASO) therapy for Angelman syndrome, is expected to enter a [...]
Wave Life Sciences to Present at Upcoming Investor Conferences
01/06/2026
CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, [...]
Fate Therapeutics Showcases Clinical Data for FT836 at the American Society of Cancer Oncology Annual Meeting
01/06/2026
FT836 demonstrates meaningful reduction in target lesions without the use of conditioning chemotherapy in metastatic colorectal cancer Detection of FT836 in the peripheral blood and tumor tissue illustrates the unique [...]
Senseonics Highlights Analyst Event and Oral Presentation of Eversense 365 Real-World Evidence at ADA 2026
01/06/2026
GERMANTOWN, Md., June 01, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable [...]
Voyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer’s Disease
01/06/2026
- Dosing of adults with early Alzheimer’s disease in clinical trial expected H2 2026 - - Comprehensive preclinical program showed compelling pharmacology and safety profile for VY1706 - - VY1706 uses an IV-delivered, [...]
Mapi Pharma to Participate in the ASCO Annual Meeting and ADA 2026 Scientific Sessions
01/06/2026
Company is seeking partnerships for the most advanced long-acting depot injections in its pipeline, including Anastrozole Depot and Semaglutide Depot NESS ZIONA, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd [...]
Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting
01/06/2026
Approximately 80% Major Response Rate and Duration of Response Exceeding 16 Months in Subset Analysis of Patients Treated with Iopofosine I 131 Immediately Post-BTKi Therapy Plans to Initiate Phase 3 Confirmatory [...]
Caring Brands Inc. and SanPellegrino Cosmetics Private Limited Announce Expanded Multi-Territory Licensing Agreement for Photocil and Hair Enzyme Booster
01/06/2026
Five-Year Agreement Extends Commercial Reach Across India, LATAM, Russia, Australia and New Zealand Fort Pierce, Fla., June 01, 2026 (GLOBE NEWSWIRE) -- Caring Brands Inc. (Nasdaq: CABR), a consumer brands company [...]
Elicio Therapeutics Announces Publication in Peer-Reviewed Journal Science Advances Highlighting Potent and Durable Immune Responses Driven by Company’s AMP-DNA Adjuvant Technology
01/06/2026
Preclinical data demonstrate robust T cell activation, durable immune memory, and lymph node-targeted mechanism supporting next-generation immunotherapies BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, [...]
Jasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value
01/06/2026
REDWOOD CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting [...]
LIXTE Biotechnology Announces Strategic Transformation into AI Energy Infrastructure Equipment & Services; Stuart D. Porter, Founder of Denham Capital, to Join Board of Directors
01/06/2026
Bringing More Than Three Decades of Energy Investment Experience, Mr. Porter Has Helped Build a Global Power Infrastructure Portfolio, Strengthening LIXTE’s Strategic Expansion into AI Energy Infrastructure BOCA RATON, [...]
GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives
01/06/2026
Increased integration of artificial intelligence–based tools across the discovery and engineering of tumor-targeting engagers and multi-domain proteins to accelerate development while reducing developmental costs [...]
Dr. Falk Pharma and Renexxion Proceed to Late-Stage Development of Naronapride, Moving Towards Approval in the US and Europe, Following Positive Global Phase 2b Results in Gastroparesis
01/06/2026
Renexxion plans to file new drug application (NDA) with the Food and Drug Administration (FDA) using future Phase 3 results ROSCREA, Ireland and FREIBURG, Germany, June 01, 2026 (GLOBE NEWSWIRE) -- Renexxion Ireland [...]
Introducing Evosep Proteomics to Standardize and Scale Proteomics for Research and Drug Development
01/06/2026
SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Evosep announces the launch of Evosep Proteomics, an ecosystem designed to standardize and scale LC-MS–based proteomics for research and pharmaceutical drug development. [...]
Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting
01/06/2026
One-time infusion of anzu-cel (anzutresgene autoleucel, IMA203) PRAME cell therapy induced rapid, deep and durable systemic anti-tumor activity in metastatic PD-1 relapsed cutaneous melanoma and metastatic uveal [...]
Disc Medicine Launches Expanded Access Program for Bitopertin for EPP Patients
01/06/2026
The expanded access program (EAP) is available to eligible patients with erythropoietic protoporphyria (EPP) and provides access to bitopertin prior to regulatory decision Bitopertin, an oral glycine transporter 1 ( [...]
Ardena appoints Ariane de Ganck as Chief Scientific Officer
01/06/2026
Ghent, Belgium, June 1, 2026 - Ardena, a specialist pharmaceutical CDMO and bioanalytical CRO enabling precision medicines and complex therapies, today announced the appointment of Ariane de Ganck, PhD, as Chief [...]

Pages